|
1
|
Modrek B and Lee C: A genomic view of
alternative splicing. Nat Genet. 30:13–19. 2002. View Article : Google Scholar
|
|
2
|
Moon H, Cho S, Yang X, Zhou J, Loh TJ,
Zheng X and Shen H: Identification of novel splicing variants from
RON proto-oncogene pre-mRNA. Oncol Rep. 28:2217–2220.
2012.PubMed/NCBI
|
|
3
|
Shen H, Zheng X, Luecke S and Green MR:
The U2AF35-related protein Urp contacts the 3′ splice site to
promote U12-type intron splicing and the second step of U2-type
intron splicing. Genes Dev. 24:2389–2394. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shen H and Green MR: RS domain-splicing
signal interactions in splicing of U12-type and U2-type introns.
Nat Struct Mol Biol. 14:597–603. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee J, Zhou J, Zheng X, Cho S, Moon H, Loh
TJ, Jo K and Shen H: Identification of a novel cis-element that
regulates alternative splicing of Bcl-x pre-mRNA. Biochem Biophys
Res Commun. 420:467–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cho S, Moon H, Yang X, Zhou J, Kim HR,
Shin MG, Loh TJ, Zheng X and Shen H: Validation of trans-acting
elements that promote exon 7 skipping of SMN2 in SMN2-GFP stable
cell line. Biochem Biophys Res Commun. 423:531–535. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen M and Manley JL: Mechanisms of
alternative splicing regulation: Insights from molecular and
genomics approaches. Nat Rev Mol Cell Biol. 10:741–754.
2009.PubMed/NCBI
|
|
8
|
Matlin AJ, Clark F and Smith CW:
Understanding alternative splicing: Towards a cellular code. Nat
Rev Mol Cell Biol. 6:386–398. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cáceres JF and Kornblihtt AR: Alternative
splicing: Multiple control mechanisms and involvement in human
disease. Trends Genet. 18:186–193. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Faustino NA and Cooper TA: Pre-mRNA
splicing and human disease. Genes Dev. 17:419–437. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cooper TA, Wan L and Dreyfuss G: RNA and
disease. Cell. 136:777–793. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kansas GS, Wood GS and Dailey MO: A family
of cell-surface glycoproteins defined by a putative
anti-endothelial cell receptor antibody in man. J Immunol.
142:3050–3057. 1989.PubMed/NCBI
|
|
13
|
Pals ST, Hogervorst F, Keizer GD, Thepen
T, Horst E and Figdor CC: Identification of a widely distributed
90-kDa glycoprotein that is homologous to the Hermes-1 human
lymphocyte homing receptor. J Immunol. 143:851–857. 1989.PubMed/NCBI
|
|
14
|
Picker LJ, Nakache M and Butcher EC:
Monoclonal antibodies to human lymphocyte homing receptors define a
novel class of adhesion molecules on diverse cell types. J Cell
Biol. 109:927–937. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fox SB, Fawcett J, Jackson DG, Collins I,
Gatter KC, Harris AL, Gearing A and Simmons DL: Normal human
tissues, in addition to some tumors, express multiple different
CD44 isoforms. Cancer Res. 54:4539–4546. 1994.PubMed/NCBI
|
|
16
|
Screaton GR, Bell MV, Bell JI and Jackson
DG: The identification of a new alternative exon with highly
restricted tissue expression in transcripts encoding the mouse
Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons
between mouse, human, and rat. J Biol Chem. 268:12235–12238.
1993.PubMed/NCBI
|
|
17
|
Ponta H, Wainwright D and Herrlich P: The
CD44 protein family. Int J Biochem Cell Biol. 30:299–305. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hofmann M, Rudy W, Günthert U, Zimmer SG,
Zawadzki V, Zöller M, Lichtner RB, Herrlich P and Ponta H: A link
between ras and metastatic behavior of tumor cells: Ras induces
CD44 promoter activity and leads to low-level expression of
metastasis-specific variants of CD44 in CREF cells. Cancer Res.
53:1516–1521. 1993.PubMed/NCBI
|
|
19
|
Weg-Remers S, Ponta H, Herrlich P and
König H: Regulation of alternative pre-mRNA splicing by the ERK
MAP-kinase pathway. EMBO J. 20:4194–4203. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Matzke A, Herrlich P, Ponta H and
Orian-Rousseau V: A five-amino-acid peptide blocks Met- and
Ron-dependent cell migration. Cancer Res. 65:6105–6110. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Orian-Rousseau V, Chen L, Sleeman JP,
Herrlich P and Ponta H: CD44 is required for two consecutive steps
in HGF/c-Met signaling. Genes Dev. 16:3074–3086. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tremmel M, Matzke A, Albrecht I, Laib AM,
Olaku V, Ballmer-Hofer K, Christofori G, Héroult M, Augustin HG,
Ponta H, et al: A CD44v6 peptide reveals a role of CD44 in VEGFR-2
signaling and angiogenesis. Blood. 114:5236–5244. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Günthert U, Hofmann M, Rudy W, Reber S,
Zöller M, Haussmann I, Matzku S, Wenzel A, Ponta H and Herrlich P:
A new variant of glycoprotein CD44 confers metastatic potential to
rat carcinoma cells. Cell. 65:13–24. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Heider KH, Kuthan H, Stehle G and Munzert
G: CD44v6: A target for antibody-based cancer therapy. Cancer
Immunol Immunother. 53:567–579. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Louderbough JM and Schroeder JA:
Understanding the dual nature of CD44 in breast cancer progression.
Mol Cancer Res. 9:1573–1586. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hill A, McFarlane S, Mulligan K, Gillespie
H, Draffin JE, Trimble A, Ouhtit A, Johnston PG, Harkin DP,
McCormick D, et al: Cortactin underpins CD44-promoted invasion and
adhesion of breast cancer cells to bone marrow endothelial cells.
Oncogene. 25:6079–6091. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ouhtit A, Abd Elmageed ZY, Abdraboh ME,
Lioe TF and Raj MH: In vivo evidence for the role of CD44s in
promoting breast cancer metastasis to the liver. Am J Pathol.
171:2033–2039. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Busch A and Hertel KJ: Evolution of SR
protein and hnRNP splicing regulatory factors. Wiley Interdiscip
Rev RNA. 3:1–12. 2012. View
Article : Google Scholar
|
|
29
|
Mayeda A, Munroe SH, Cáceres JF and
Krainer AR: Function of conserved domains of hnRNP A1 and other
hnRNP A/B proteins. EMBO J. 13:5483–5495. 1994.PubMed/NCBI
|
|
30
|
Martinez-Contreras R, Cloutier P, Shkreta
L, Fisette JF, Revil T and Chabot B: hnRNP proteins and splicing
control. Adv Exp Med Biol. 623:123–147. 2007. View Article : Google Scholar
|
|
31
|
Zhou ZJ, Dai Z, Zhou SL, Fu XT, Zhao YM,
Shi YH, Zhou J and Fan J: Overexpression of HnRNP A1 promotes tumor
invasion through regulating CD44v6 and indicates poor prognosis for
hepatocellular carcinoma. Int J Cancer. 132:1080–1089. 2013.
View Article : Google Scholar
|
|
32
|
van Weering DH, Baas PD and Bos JL: A
PCR-based method for the analysis of human CD44 splice products.
PCR Methods Appl. 3:100–106. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Afify A, Purnell P and Nguyen L: Role of
CD44s and CD44v6 on human breast cancer cell adhesion, migration,
and invasion. Exp Mol Pathol. 86:95–100. 2009. View Article : Google Scholar : PubMed/NCBI
|
